Tarsus Pharmaceuticals, Inc. Stock News

Tarsus Pharmaceuticals Inc (TARS) shares closed 1.2% lower than its previous 52 week low, giving the company a market cap of $446M. The stock is currently down 4.0% year-to-date, down 49.7% over the past 12 months, and up 5.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 11.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 1564.0% The company's stock price performance over the past 12 months lags the peer average by 214.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Tarsus Pharmaceuticals Inc (TARS) shares closed today 11.4% higher than it did at the end of yesterday. The stock is currently down 35.0% year-to-date, down 39.1% over the past 12 months, and up 30.6% over the past five years. Today, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 1.8%. Trading Activity Shares traded as high as $26.95 and as low as $23.69 this week.Shares closed 46.2% below its 52-week high and 28.0% above its 52-week low.Trading volume this week was 62.9% higher than the 10-day average and 61.7% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 17.2% The company's stock price performance over the past 12 months lags the peer average by 26.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Nuveen Asset Management LLC lifted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 73.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,723 shares of the companys stock after buying an additional 10,891 shares during the quarter. Nuveen Asset [] The post Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Nuveen Asset Management LLC appeared first on ETF Daily News .

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Equities research analysts at Oppenheimer issued their FY2021 earnings estimates for Tarsus Pharmaceuticals in a research note issued to investors on Monday, November 22nd. Oppenheimer analyst F. Brisebois expects that the company will post earnings of ($0.48) per share for the year. Oppenheimer currently has a Outperform rating and a []

Oppenheimer started coverage on shares of Tarsus Pharmaceuticals (NASDAQ:TARS) in a research note issued to investors on Monday morning, PriceTargets.com reports. The brokerage issued an outperform rating and a $55.00 price objective on the stock. Several other research analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Tarsus Pharmaceuticals […]

IRVINE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in the following virtual investor conferences:

IRVINE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Jefferies Financial Group issued their Q1 2022 earnings per share estimates for shares of Tarsus Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 10th. Jefferies Financial Group analyst A. Petrone forecasts that the company will post earnings per share of ($1.18) for the quarter. Jefferies []

Vanguard Group Inc. raised its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 56.1% in the second quarter, Holdings Channel reports. The fund owned 426,045 shares of the companys stock after buying an additional 153,055 shares during the quarter. Vanguard Group Inc.s holdings in Tarsus Pharmaceuticals were worth $12,347,000 as of its most recent []

Ms. Crane brings over 30 years of experience in executive leadership, commercialization, and business development in the pharmaceutical and healthcare industries

Announced positive results of the Saturn-1 pivotal trial evaluating TP-03 for the treatment of Demodex blepharitis; results presented at the 2021 American Society of Cataract and Refractive Surgery (A

New Saturn-1 data demonstrated a strong patient responder rate with 95% of Demodex blepharitis patients treated with TP-03 achieving ≤0.5 mites per lash and 93% improving by at least one collarette

IRVINE, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven

These three biotech stocks recently had positive news coming out of phase 2 trials, making them good choices for growth-oriented investors.

IRVINE, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven